[Congressional Record Volume 165, Number 110 (Friday, June 28, 2019)]
[Senate]
[Page S4676]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




                         REPORTS OF COMMITTEES

  The following reports of committees were submitted:

       By Mr. GRAHAM, from the Committee on the Judiciary, with an 
     amendment in the nature of a substitute:
       S. 440. A bill to amend title 35, United States Code, to 
     provide that a patent owner may not assert sovereign immunity 
     as a defense in certain actions before the United States 
     Patent and Trademark Office, and for other purposes.


 =========================== NOTE =========================== 

  
  On page S4676, June 28, 2019, in the third column, the following 
appears: From the Committee on the Judiciary, with an amendment in 
the nature of a substitute: S. 440. A bill to amend title 35 . . .
  
  The online Record has been corrected to read:By Mr. GRAHAM, from 
the Committee on the Judiciary, with an amendment in the nature of 
a substitute: S. 440. A bill to amend title 35 . . .


 ========================= END NOTE ========================= 


       By Mr. GRAHAM, from the Committee on the Judiciary, with an 
     amendment in the nature of a substitute and an amendment to 
     the title:
       S. 1224. A bill to enable the Federal Trade Commission to 
     deter filing of sham citizen petitions to cover an attempt to 
     interfere with approval of a competing generic drug or 
     biosimilar, to foster competition, and facilitate the 
     efficient review of petitions filed in good faith to raise 
     legitimate public health concerns, and for other purposes.
       By Mr. GRAHAM, from the Committee on the Judiciary, with an 
     amendment in the nature of a substitute:
       S. 1227. A bill to require the Federal Trade Commission to 
     study the role of intermediaries in the pharmaceutical supply 
     chain and provide Congress with appropriate policy 
     recommendations, and for other purposes.
       S. 1416. A bill to amend the Federal Trade Commission Act 
     to prohibit anticompetitive behaviors by drug product 
     manufacturers, and for other purposes.

                          ____________________